ArticleThe oncologist2026

Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation.

Galip Can Uyar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.